封面
市場調查報告書
商品編碼
927773

冠狀動脈疾病治療的全球市場:成長,趨勢,預測(2020年~2025年)

Coronary Artery Disease Therapeutics Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 105 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球冠狀動脈疾病治療市場在2020年~2025年的預測期間內預計將以5.5%的年複合成長率增長。冠狀動脈疾病(CAD),也稱為缺血性心臟疾病(IHD)及冠狀動脈心臟疾病(CHD),是一種由脂肪物質和斑塊在冠狀動脈中積聚引起冠狀動脈狹窄或阻塞的疾病。隨著全球性高血壓,高膽固醇,糖尿病和肥胖症的發病率和患病率增加,政府為提高對疾病的認識和加大對研發活動的投資的努力是冠狀動脈疾病治療市場上主要推動要素。

本報告提供全球冠狀動脈疾病治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各市場區隔和各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 老年人口的增加和慢性疾病的發生率上升
    • 冠狀動脈疾病治療藥的研究開發投資增加
  • 阻礙市場要素
    • 昂貴
    • 償付的問題
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔

  • 各藥物類別
    • Statin
    • β- 阻斷劑
    • 鈣通道阻斷劑
    • ACE抑制劑(血管收縮素轉換酵素抑制劑)
    • 抗血小板藥
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca Plc
    • Gilead Sciences, Inc
    • Novartis AG
    • Pfizer Inc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline Plc
    • Merck & Co., Inc
    • Teva Pharmaceutical Industries Ltd
    • Mylan NV

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 68293

The Coronary Artery Disease Therapeutics Market is expected to register a CAGR of 5.5% during the forecast period. Coronary Artery Disease (CAD) also known as ischemic heart disease (IHD) and coronary heart diseases (CHD) is a disease in which there is a narrowing or blockage of the coronary arteries due to buildup of fatty material and plaque inside the coronary arteries. These fatty material and plaque can restrict blood flow to the heart muscle by physically clogging the artery or by causing abnormal artery tone and function. Without an adequate blood supply to the heart, the heart becomes starved of oxygen which may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms. A complete blockage can cause a heart attack. Coronary artery disease is thought to begin with injury or damage to the inner layer of a coronary artery. Damage may be caused by various factors, such as Smoking, Sedentary lifestyle, diabetes or insulin resistance, high blood pressure and high cholesterol. Some of the risk factors for coronary artery disease include age, sex, family history, obesity, and high stress among others.

According to the World Heart Federation, Coronary heart disease is now the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. In addition, 80% of the deaths occur in low- and middle-income countries.

Growing incidence and prevalence rate of hypertension, high cholesterol, diabetes, and obesity across the world, government initiatives to increase the awareness toward disease and increasing investment on research and development activity are the key driving factors in coronary artery disease therapeutics market.

Key Market Trends

Statins Segment is Expected to Hold a Major Market Share in the Coronary Artery Disease Therapeutics Market

  • Statin medications are drugs that help to lower cholesterol levels in the blood and prevent coronary heart disease. Statins are the first-line treatment of choice for patients with coronary heart disease and high cholesterol levels. Statins have additional benefits such as improvements in endothelial function, reduction in the amount of inflammation and damage done to cells through oxidation stress and prevention of platelet aggregation, thereby reducing the risk of a blood clot (thrombus).
  • Statins segment holds a significant market share in the coronary artery disease therapeutics market and is anticipated to show a similar trend over the forecast period due to ability to reduce mortality and cardiovascular events in patients with coronary artery disease or at high risk of cardiovascular disease.
  • Increasing incidences of chronic diseases especially in developed countries, and growing awareness regarding early diagnosis of diseases, are the key driving factors in the statins segment.
  • According to the Heart Foundation, in Australia, Coronary heart disease (CHD) was the main cause for 160,400 hospitalizations in the years 2016-17. Furthermore, heart disease was a factor in nearly one in four deaths in the year 2017.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global coronary artery disease therapeutics market due to the growing geriatric population, and increasing incidences of chronic diseases. According to the Centers for Disease Control and Prevention, in the year 2017, coronary heart disease is the most common type of heart disease, killing approximately 365,914 people in the United States. Moreover, about 18.2 million adults age 20 and older have Coronary heart disease (CAD). Furthermore, high healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Coronary Artery Disease Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AstraZeneca Plc, Gilead Sciences, Inc, Novartis AG, Pfizer Inc, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd and Mylan N.V.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Geriatric Population and Associated Increase in Incidences of Chronic Disease
    • 4.2.2 Increasing Investment on R&D of Coronary Artery Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 High Costs of Treatment
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Statins
    • 5.1.2 Beta-blockers
    • 5.1.3 Calcium Channel Blockers
    • 5.1.4 ACE Inhibitors
    • 5.1.5 Antiplatelet Drugs
    • 5.1.6 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca Plc
    • 6.1.2 Gilead Sciences, Inc
    • 6.1.3 Novartis AG
    • 6.1.4 Pfizer Inc
    • 6.1.5 Bayer AG
    • 6.1.6 Bristol-Myers Squibb Company
    • 6.1.7 GlaxoSmithKline Plc
    • 6.1.8 Merck & Co., Inc
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 Mylan N.V.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS